Accelerating Preclinical TCE Development for Autoimmune Disease Therapies
Vivia Biotech offers comprehensive assays for TCE development in Autoimmune Diseases.
- Access to fresh patient samples: High-quality samples from patients with rheumatoid arthritis, lupus, multiple sclerosis, and other autoimmune diseases.
- Deep expertise in TCE evaluation: We have assessed over 30 diverse TCEs from pharma companies, including CD3xCD20 and CD3xCD38
- Patented native environment assays: These assays utilize patient-derived samples and complex cellular interactions, providing a more accurate representation of TCE performance in the body.
- Efficacy assays using flow cytometry:
- Measure target expression of your TCE revealing the interpatient variability.
- Target selectivity of activated T cells: TCE effects on non-target cells.
- Activity on different types of B cells.
- Cytokine and immunoglobulins release.
- Differentiate distinct TCE formats aimed at the same target.
- Reveal critical differences in killing activity for each TCE format.
- Select the best TCE format still in the discovery phase.
- Combine TCE with Immune Checkpoint Inhibitors (ICIs): evaluate activity of ICIS in a functional assay to reverse resistance, enhancing B cell killing.
Vivia’s ex vivo assays can help to improve your TCE compound for autoimmune diseases.